{"organizations": [], "uuid": "8262c7a57d7911ea2b19679015d67eec9a8f8703", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://www.reuters.com/resources/archive/us/20180124.html", "section_title": "Archive News &amp; Video for Wednesday, 24 Jan 2018 | Reuters.com", "url": "https://www.reuters.com/article/brief-ocular-therapeutix-announces-propo/brief-ocular-therapeutix-announces-proposed-public-offering-of-common-stock-idUSASB0C26J", "country": "US", "domain_rank": 408, "title": "BRIEF-Ocular Therapeutix Announces Proposed Public Offering Of Common Stock", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.049, "site_type": "news", "published": "2018-01-25T05:19:00.000+02:00", "replies_count": 0, "uuid": "8262c7a57d7911ea2b19679015d67eec9a8f8703"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/brief-ocular-therapeutix-announces-propo/brief-ocular-therapeutix-announces-proposed-public-offering-of-common-stock-idUSASB0C26J", "ord_in_thread": 0, "title": "BRIEF-Ocular Therapeutix Announces Proposed Public Offering Of Common Stock", "locations": [], "entities": {"persons": [], "locations": [], "organizations": [{"name": "reuters", "sentiment": "negative"}, {"name": "ocular therapeutix inc", "sentiment": "negative"}, {"name": "eikon", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "Jan 24 (Reuters) - Ocular Therapeutix Inc:\n* OCULAR THERAPEUTIXâ„¢ ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK\n* OCULAR THERAPEUTIX - TO USE PROCEEDS FROM OFFERING, EXISTING CASH AND EQUIVALENTS, TO FUND PLANNED RESUBMISSION OF NEW DRUG APPLICATION FOR DEXTENZA\n* OCULAR THERAPEUTIX - TO ALSO USE PROCEEDS TO FUND CLINICAL DEVELOPMENT OF OTX-TP, OTX-TIC AND OTX-TKI, ADDITIONAL PRECLINICAL, REGULATORY ACTIVITIES Source text for Eikon: Further company coverage:\n ", "external_links": ["http://thomsonreuters.com/en/about-us/trust-principles.html"], "published": "2018-01-25T05:19:00.000+02:00", "crawled": "2018-01-25T13:18:59.000+02:00", "highlightTitle": ""}